Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luke A O'Neill

Showing results (1-10 of 57) with videos related to

Pageof 6
Sort By:
Science (New York, N.Y.)|May 10, 2011
Retrospective. Jürg Tschopp (1951-2011)Luke A O'Neill
Molecular Interventions|March 3, 2004
IRAK-4: a new drug target in inflammation, sepsis, and autoimmunityClaudia Wietek, Luke A O'Neill
Cell Research|May 31, 2018
Dimethyl fumarate: targeting glycolysis to treat MSStefano Angiari, Luke A O'Neill
The New England Journal of Medicine|January 12, 2018
Canakinumab for Atherosclerotic DiseaseLuke A O'Neill, Matthew A Cooper
European Journal of Immunology|September 29, 2011
MicroRNAs and the resolution phase of inflammation in macrophagesMuhammad M Alam, Luke A O'Neill
IUBMB Life|August 29, 2013
Mal, more than a bridge to MyD88Nicholas J Bernard, Luke A O'Neill
Trends in Immunology|January 18, 2020
ACLY-matizing Macrophages to Histone Modification during Immunometabolic ReprogrammingNiamh C Williams, Luke A O'Neill
Current Topics in Microbiology and Immunology|July 10, 2014
The role of microRNAs in the control and mechanism of action of IL-10Susan R Quinn, Luke A O'Neill
Journal of Leukocyte Biology|May 31, 2012
miR-107: a toll-like receptor-regulated miRNA dysregulated in obesity and type II diabetesNiamh H Foley, Luke A O'Neill
International Immunology|June 10, 2011
A trio of microRNAs that control Toll-like receptor signallingSusan R Quinn, Luke A O'Neill
Pageof 6

Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
Science (New York, N.Y.)|May 10, 2011
Retrospective. Jürg Tschopp (1951-2011)Luke A O'Neill
Molecular Interventions|March 3, 2004
IRAK-4: a new drug target in inflammation, sepsis, and autoimmunityClaudia Wietek, Luke A O'Neill
Cell Research|May 31, 2018
Dimethyl fumarate: targeting glycolysis to treat MSStefano Angiari, Luke A O'Neill
The New England Journal of Medicine|January 12, 2018
Canakinumab for Atherosclerotic DiseaseLuke A O'Neill, Matthew A Cooper
European Journal of Immunology|September 29, 2011
MicroRNAs and the resolution phase of inflammation in macrophagesMuhammad M Alam, Luke A O'Neill
IUBMB Life|August 29, 2013
Mal, more than a bridge to MyD88Nicholas J Bernard, Luke A O'Neill
Trends in Immunology|January 18, 2020
ACLY-matizing Macrophages to Histone Modification during Immunometabolic ReprogrammingNiamh C Williams, Luke A O'Neill
Current Topics in Microbiology and Immunology|July 10, 2014
The role of microRNAs in the control and mechanism of action of IL-10Susan R Quinn, Luke A O'Neill
Journal of Leukocyte Biology|May 31, 2012
miR-107: a toll-like receptor-regulated miRNA dysregulated in obesity and type II diabetesNiamh H Foley, Luke A O'Neill
International Immunology|June 10, 2011
A trio of microRNAs that control Toll-like receptor signallingSusan R Quinn, Luke A O'Neill
Pageof 6